StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
PHG-R.BK$10.60+0.00%
Fair $10.60+0.0%

PHG-R.BK

Patrangsit Healthcare Group Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$10.60

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $10.60Fund rank 38/100 · Data gapFallback financials|
SA 59/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 22% · confianza 25%

FCF escenarios

weak_data · normalized FCF $235.1M · quality 82.7/100

Data gap 38/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 85/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

59/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · PHG-R.BKLocal privado en este navegador · Patrangsit Healthcare Group Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3.2B

P/E

10.3x

↓

EV/EBITDA

5.8x

↓

ROE

14.0%

↑

Gross Margin

25.0%

↓

Debt/Equity

0.00

↓
52-Week Range$11
$10$11

TradingView lightweight chart

PHG-R.BK price, volumen y niveles de valoración

Último $10.60Periodo +0.0%
Fair value: $10.60

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+7.1%

FCF CAGR

+6.2%

FCF margin

11.8%

FCF / Net income

0.96x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.51B · net income $309.5M · FCF $296.6M

2022-FY → 2025-FY

Gross margin

25.0%-4.8% pts

Operating margin

15.5%-3.1% pts

Net margin

12.3%-2.0% pts

FCF margin

11.8%-0.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.51B$2.51B$2.27B$2.14B$2.04B
Net Income$309.5M$309.5M$252.2M$259.5M$293.1M
EBITDA$493.5M$493.5M$411.2M$417.1M$449.8M
EPS1.031.030.840.950.98
Gross Margin25.0%25.0%23.5%26.8%29.8%
Operating Margin15.5%15.5%13.9%15.6%18.6%
Net Margin12.3%12.3%11.1%12.1%14.4%
Balance Sheet
Debt/Equity0.000.000.000.030.34
Current Ratio4.614.61———
Cash Flow
Free Cash Flow$296.6M$296.6M$210.3M$235.1M$247.3M
Returns
ROE14.0%14.0%12.3%13.2%30.0%
Valuation
P/E10.2910.29———
EV/EBITDA5.785.78———
P/B1.441.44———
Growth & Yield
Revenue Growth10.3%10.3%6.3%4.8%—
EPS Growth22.6%22.6%-11.6%-2.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-3.0%

fácil

EPS terminal req.

$0.94

Spread vs growth

25.6%

5Y implied EPS CAGR

2.0%

fácil

EPS terminal req.

$1.14

Spread vs growth

20.6%

10Y implied EPS CAGR

5.9%

razonable

EPS terminal req.

$1.83

Spread vs growth

16.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total +0.0%

Total return

+0.0%

Start / end P/E

12.6x → 10.3x

EPS bridge

0.84 → 1.03

Residual

-4.2%

EPS growth+22.6%
Multiple rerating-18.4%
Dividend+0.0%
Residual / FX / buybacks / cross-term-4.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.